NCT00942734 2025-05-01
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
9 trialsNCT00936858 2021-10-22
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01270321 2021-02-17
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Emory University
Phase 2 Completed
NCT01333085 2016-02-10
CAPRA
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 1/2 Completed
NCT01283334 2014-12-04
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
Emory University
Phase 1/2 Completed
NCT01164176 2014-12-02
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Yonsei University
Phase 2 Completed
NCT00935961 2013-08-09
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00858663 2013-07-25
Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01637194 2012-07-11
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
Fox Chase Cancer Center
Phase 1 Completed